Dr Reddy’s Debuts Two Revlimid Exclusives As Part Of Complete Launch In US
End Of Teva Exclusivity Period Opens Door For Several Lenalidomide ANDA Approvals
Dr Reddy’s Laboratories is set to reap the rewards of a significant US generic launch – albeit one with a limited volume caveat decreed by a patent-litigation settlement deal – after it began selling its generic of Bristol Myers Squibb’s multi-billion-dollar blockbuster Revlimid.
You may also be interested in...
Months after the first generic versions of Bristol-Myers Squibb’s multi-billion-dollar blockbuster Revlimid (lenalidomide) debuted in the US, indirect purchasers of the treatment for multiple myeloma have accused the originator and a raft of settling ANDA sponsors that their deals were anticompetitive.
Generic Revlimid US sales propel Dr Reddy’s to a record fiscal second quarter, with the management indicating that “meaningful” contributions are likely in the coming months too. The Indian firm also expects to deploy its healthy cash flows for deal-making, aided by tempered valuations in some segments amid geopolitical and economic turbulence.
Zydus is set to join Natco in chipping away at BMS’ blockbuster Revlimid with its generic version, probably from Q2 while Aurobindo expects to launch by FY24. Revenues from this drug are expected to offset erosion of generic Asacol revenues even as Zydus expects volume growth and new launches to help grow its US business.